Table 4.

Overview of MRD data from relevant studies of novel agents

Study	Treatment	Line of therapy	MRD method/threshold	N patients	% uMRD ITT	MRD-guided treatment?
Ahn et al 201846	Ibrutinib	TN, r/r	Flow, 10−4, pB	86	6	No
von Tresckow et al 201947	(Bendamustine), ibrutinib, obinutuzumab	TN, r/r	Flow, 10−4, pB	61	44	Yes
Fraser et al 201912	Ibrutinib plus BR	r/r	Flow, 10−4, pB/BM	289	18	No
Stilgenbauer et al 201821	Venetoclax	r/r	Flow, 10−4, pB	158	30	No
Seymour et al 201822	Venetoclax, rituximab	r/r	Flow/PCR, 10−4, pB	194	64	No
Cramer et al 201838	(Bendamustine), venetoclax, obinutuzumab	TN, r/r	Flow, 10−4, pB	66	83	Yes
Fischer et al, 201949	Venetoclax, obinutuzumab	TN	ASO-PCR, 10−4, pB/BM	216	75/57	No
Hillmen et al 201850	Venetoclax, ibrutinib	r/r	Flow, 10−4, pB	40	58	Yes
Jain et al 201951	Venetoclax, ibrutinib	TN	Flow, 10−4, BM	33	61	No

ASO, allele-specific oligonucleotide; BM, bone marrow; ITT, inverstigator initiated trial; pB, peripheral blood; r/r, relapsed or refractory; TN, treatment naive.